Eptacog alfa, activated
Eptacog alfa, activated is a biological therapy with 24 clinical trials. Historical success rate of 87.0%.
Success Metrics
Based on 20 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
5
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.3%
20 of 24 finished
16.7%
4 ended early
0
trials recruiting
24
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
Clinical Trials (24)
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
Use of Activated Recombinant FVII in Spinal Surgery
Trial of NovoSeven® in Haemophilia - Joint Bleeds
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
PROPACT: Retrospective Prophylaxis Patient Case Collection
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
Factor VIIa in Acute Intracerebral Haemorrhage
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 24